What is the AQUAx2 Study?
The AQUAx2 study is a clinical research study for people with dry mouth (xerostomia) caused by radiation therapy from previous head and neck cancer. The purpose of this study is to assess the efficacy and safety of a new investigational gene transfer study drug, called AAV2-hAQP1, at helping with dry mouth resulting from radiation damage to the parotid salivary glands.
Who can participate in the AQUAx2 Study?
Patients with abnormal parotid saliva gland function (resulting in dry mouth) must meet certain criteria to qualify for the study. If you are an interested patient, you may review our criteria and see if you qualify.
What is Xerostomia?
Xerostomia (dry mouth) is a condition in which a person’s parotid salivary glands do not produce enough saliva. It can be caused by damage from radiation therapy for conditions like head and neck cancer. Currently, there is no cure for xerostomia. Most therapies focus on managing the symptoms.
Visit our Frequently Asked Questions page
If you have more questions or would like to explore online resources with useful information, visit our Resources page.